Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

In Vivo Gene Therapy for Mucopolysaccharidosis Type III (Sanfilippo Syndrome): A New Treatment Horizon

  • Marcó, Sara|||0000-0003-3502-5198
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
For most lysosomal storage diseases (LSDs), there is no cure. Gene therapy is an attractive tool for treatment of LSDs caused by deficiencies in secretable lysosomal enzymes, in which neither full restoration of normal enzymatic activity nor transduction of all cells of the affected organ is necessary. However, some LSDs, such as mucopolysaccharidosis type III (MPSIII) diseases or Sanfilippo syndrome, represent a difficult challenge because patients suffer severe neurodegeneration with mild somatic alterations. The disease's main target is the central nervous system (CNS) and enzymes do not efficiently cross the blood-brain barrier (BBB) even if present at very high concentration in circulation. No specific treatment has been approved for MPSIII. In this study, we discuss the adeno-associated virus (AAV) vector-mediated gene transfer strategies currently being developed for MPSIII disease. These strategies rely on local delivery of AAV vectors to the CNS either through direct intraparenchymal injection at several sites or through delivery to the cerebrospinal fluid (CSF), which bathes the whole CNS, or exploit the properties of certain AAV serotypes capable of crossing the BBB upon systemic administration. Although studies in small and large animal models of MPSIII diseases have provided evidence supporting the efficacy and safety of all these strategies, there are considerable differences between the different routes of administration in terms of procedure-associated risks, vector dose requirements, sensitivity to the effect of circulating neutralizing antibodies that block AAV transduction, and potential toxicity. Ongoing clinical studies should shed light on which gene transfer strategy leads to highest clinical benefits while minimizing risks. The development of all these strategies opens a new horizon for treatment of not only MPSIII and other LSDs but also of a wide range of neurological diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Seven-year follow-up of durability and safety of AAV CNS gene therapy for a lysosomal storage disorder in a large animal

  • Marcó, Sara|||0000-0003-3502-5198
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Jaén Sitges, Maria Luisa|||0000-0002-9188-0810
  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Sánchez Clares, Víctor|||0000-0001-8631-9239
  • Molas, Maria
  • Garcia, Miquel|||0000-0002-1602-4993
  • León, Xavier|||0000-0002-8393-2721
  • Roca Lecha, Carles|||0000-0002-3744-3089
  • Sanchez Moreno, Xavier|||0000-0003-0897-0661
  • Bertolín Gálvez, Joan|||0000-0002-5196-0955
  • Pérez, Jennifer
  • Elias Bosch, Gemma|||0000-0003-1985-7955
  • Navarro Beltrán, Marc|||0000-0002-9678-6129
  • Carretero i Romay, Ana|||0000-0001-9377-4926
  • Pumarola i Batlle, Martí|||0000-0002-0935-7941
  • Andaluz Martínez, Anna|||0000-0001-8097-8110
  • Espada, Yvonne|||0000-0003-1556-6587
  • Añor Torres, Sònia|||0000-0002-1099-7698
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Delivery of adeno-associated viral vectors (AAVs) to cerebrospinal fluid (CSF) has emerged as a promising approach to achieve widespread transduction of the central nervous system (CNS) and peripheral nervous system (PNS), with direct applicability to the treatment of a wide range of neurological diseases, particularly lysosomal storage diseases. Although studies in small animal models have provided proof of concept and experiments in large animals demonstrated feasibility in bigger brains, there is not much information on long-term safety or durability of the effect. Here, we report a 7-year study in healthy beagle dogs after intra-CSF delivery of a single, clinically relevant dose (2 × 10 13 vg/dog) of AAV9 vectors carrying the canine sulfamidase, the enzyme deficient in mucopolysaccharidosis type IIIA. Periodic monitoring of CSF and blood, clinical and neurological evaluations, and magnetic resonance and ultrasound imaging of target organs demonstrated no toxicity related to treatment. AAV9-mediated gene transfer resulted in detection of sulfamidase activity in CSF throughout the study. Analysis at tissue level showed widespread sulfamidase expression and activity in the absence of histological findings in any region of encephalon, spinal cord, or dorsal root ganglia. Altogether, these results provide proof of durability of expression and long-term safety for intra-CSF delivery of AAV-based gene transfer vectors encoding therapeutic proteins to the CNS. Seven-year follow-up of dogs after intra-CSF administration of AAV9-sulfamidase vectors results in detection of sulfamidase activity in CSF and widespread transgene expression in CNS, PNS, and liver, in the absence of any adverse events. Proof of durability and safety of this gene therapy support its clinical translation to treat CNS diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Treatment of skeletal and non-skeletal alterations of Mucopolysaccharidosis type IVA by AAV-mediated gene therapy

  • Bertolín Gálvez, Joan|||0000-0002-5196-0955
  • Sánchez Clares, Víctor|||0000-0001-8631-9239
  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Jaén Sitges, Maria Luisa|||0000-0002-9188-0810
  • Garcia, Miquel|||0000-0002-1602-4993
  • Pujol i Altarriba, Anna|||0000-0002-3484-598X
  • Sanchez Moreno, Xavier|||0000-0003-0897-0661
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Marcó, Sara|||0000-0003-3502-5198
  • Pérez, Jennifer
  • Elias Bosch, Gemma|||0000-0003-1985-7955
  • León, Xavier|||0000-0002-8393-2721
  • Roca Lecha, Carles|||0000-0002-3744-3089
  • Jimenez, Veronica|||0000-0001-9145-9877
  • Otaegui Goya, Pedro José
  • Mulero, Francisca|||0000-0001-9584-4211
  • Navarro Beltrán, Marc|||0000-0002-9678-6129
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Mucopolysaccharidosis type IVA (MPSIVA) or Morquio A disease, a lysosomal storage disorder, is caused by N -acetylgalactosamine-6-sulfate sulfatase (GALNS) deficiency, resulting in keratan sulfate (KS) and chondroitin-6-sulfate accumulation. Patients develop severe skeletal dysplasia, early cartilage deterioration and life-threatening heart and tracheal complications. There is no cure and enzyme replacement therapy cannot correct skeletal abnormalities. Here, using CRISPR/Cas9 technology, we generate the first MPSIVA rat model recapitulating all skeletal and non-skeletal alterations experienced by patients. Treatment of MPSIVA rats with adeno-associated viral vector serotype 9 encoding Galns (AAV9- Galns) results in widespread transduction of bones, cartilage and peripheral tissues. This led to long-term (1 year) increase of GALNS activity and whole-body correction of KS levels, thus preventing body size reduction and severe alterations of bones, teeth, joints, trachea and heart. This study demonstrates the potential of AAV9- Galns gene therapy to correct the disabling MPSIVA pathology, providing strong rationale for future clinical translation to MPSIVA patients. Mucopolysaccharidosis type IVA (MPSIVA) is a lysosomal storage disorder causing severe skeletal and non-skeletal alterations in patients. Here, the authors generate a MPSIVA rat model that mimics the disabling human pathology and develop an AAV9-Galns gene therapy to treat the disease.